China
· Delayed Price · Currency is CNY DaShenLin Pharmaceutical Group Statistics
Total Valuation
DaShenLin Pharmaceutical Group has a market cap or net worth of CNY 18.31 billion. The enterprise value is 21.17 billion.
| Market Cap | 18.31B |
| Enterprise Value | 21.17B |
Important Dates
The last earnings date was Tuesday, October 29, 2024.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | Oct 23, 2024 |
Share Statistics
DaShenLin Pharmaceutical Group has 1.14 billion shares outstanding. The number of shares has decreased by -0.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.14B |
| Shares Change (YoY) | -0.25% |
| Shares Change (QoQ) | +3.17% |
| Owned by Insiders (%) | 64.55% |
| Owned by Institutions (%) | 8.33% |
| Float | 403.75M |
Valuation Ratios
The trailing PE ratio is 21.47 and the forward PE ratio is 18.64.
| PE Ratio | 21.47 |
| Forward PE | 18.64 |
| PS Ratio | 0.69 |
| PB Ratio | 2.67 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.31 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.54, with an EV/FCF ratio of 14.23.
| EV / Earnings | 24.90 |
| EV / Sales | 0.80 |
| EV / EBITDA | 7.54 |
| EV / EBIT | 15.36 |
| EV / FCF | 14.23 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 0.90.
| Current Ratio | 0.92 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 2.61 |
| Debt / FCF | 4.92 |
| Interest Coverage | 5.91 |
Financial Efficiency
Return on equity (ROE) is 11.53% and return on invested capital (ROIC) is 5.96%.
| Return on Equity (ROE) | 11.53% |
| Return on Assets (ROA) | 3.64% |
| Return on Capital (ROIC) | 5.96% |
| Revenue Per Employee | 583,716 |
| Profits Per Employee | 18,701 |
| Employee Count | 45,466 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 4.13 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.45% in the last 52 weeks. The beta is 0.30, so DaShenLin Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -37.45% |
| 50-Day Moving Average | 14.74 |
| 200-Day Moving Average | 17.84 |
| Relative Strength Index (RSI) | 55.99 |
| Average Volume (20 Days) | 16,799,682 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DaShenLin Pharmaceutical Group had revenue of CNY 26.54 billion and earned 850.26 million in profits. Earnings per share was 0.75.
| Revenue | 26.54B |
| Gross Profit | 9.01B |
| Operating Income | 1.38B |
| Pretax Income | 1.22B |
| Net Income | 850.26M |
| EBITDA | 1.60B |
| EBIT | 1.38B |
| Earnings Per Share (EPS) | 0.75 |
Balance Sheet
The company has 5.72 billion in cash and 7.32 billion in debt, giving a net cash position of -1.60 billion or -1.40 per share.
| Cash & Cash Equivalents | 5.72B |
| Total Debt | 7.32B |
| Net Cash | -1.60B |
| Net Cash Per Share | -1.40 |
| Equity (Book Value) | 8.13B |
| Book Value Per Share | 6.03 |
| Working Capital | -1.08B |
Cash Flow
In the last 12 months, operating cash flow was 3.20 billion and capital expenditures -1.71 billion, giving a free cash flow of 1.49 billion.
| Operating Cash Flow | 3.20B |
| Capital Expenditures | -1.71B |
| Free Cash Flow | 1.49B |
| FCF Per Share | 1.31 |
Margins
Gross margin is 33.95%, with operating and profit margins of 5.19% and 3.20%.
| Gross Margin | 33.95% |
| Operating Margin | 5.19% |
| Pretax Margin | 4.58% |
| Profit Margin | 3.20% |
| EBITDA Margin | 6.03% |
| EBIT Margin | 5.19% |
| FCF Margin | 5.61% |
Dividends & Yields
This stock pays an annual dividend of 0.62, which amounts to a dividend yield of 3.81%.
| Dividend Per Share | 0.62 |
| Dividend Yield | 3.81% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 43.91% |
| Buyback Yield | 0.25% |
| Shareholder Yield | 4.07% |
| Earnings Yield | 4.66% |
| FCF Yield | 8.12% |
Stock Splits
The last stock split was on June 9, 2023. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 9, 2023 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
DaShenLin Pharmaceutical Group has an Altman Z-Score of 2.17. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | n/a |